Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Forensic Science, Medicine and Pathology
Published in: Forensic Science, Medicine and Pathology 4/2017

01-12-2017 | Case Report

Sudden death due to malignant hyperthermia with a mutation of RYR1: autopsy, morphology and genetic analysis

Authors: Wenhe Li, Lin Zhang, Yue Liang, Fang Tong, Yiwu Zhou

Published in: Forensic Science, Medicine and Pathology | Issue 4/2017

Login to get access

Abstract

Malignant hyperthermia (MH) is an autosomal dominant disorder characterized by abnormal calcium homeostasis in skeletal muscles in response to triggering agents. Autopsy, morphology, and genetic analysis were performed on a 19-year-old man who died rapidly after exposure to sevoflurane during maxillofacial surgery. Muscle spasm around the operation area and limb rigidity occurred and renal tubules full of myoglobin casts were observed by microscopy. Ultrastructural changes in the skeletal muscles and the myocardium were detected by transmission electron microscopy (TEM). Genetic analysis disclosed a ryanodine receptor type 1 (RYR1) gene mutation and a nucleoide mutation in chromosome 19q (G1021A) in the deceased and his father. According to the fore mentioned results, the relationship between the cause of death and MH was confirmed. Thus, genetic analysis can be an important procedure in diagnosing MH.
Literature
1.
Denborough MA, Forster JF, Lovell RR, Maplestone PA, Villiers JD. Anaesthetic deaths in a family. Br J Anaesth. 1962;34:395.CrossRefPubMed
2.
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States. Anesth Analg. 2014;119:1359–66.CrossRefPubMed
3.
Girard T, Urwyler A, Censier K, Mueller CR, Zorzato F, Treves S. Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat. 2001;18:357–8.CrossRefPubMed
4.
Karger B, Teige K. Fatal malignant hyperthermia—delayed onset and atypical course. Forensic Sci Int. 2002;129:187–90.CrossRefPubMed
5.
Nishio H, Sato T, Fukunishi S, Tamura A, Iwata M, Tsuboi K, et al. Identification of malignant hyperthermia-susceptible ryanodine receptor type 1 gene (RYR1) mutations in a child who died in a car after exposure to a high environmental temperature. Legal Med. 2009;11:142–3.CrossRefPubMed
6.
Migita T, Mukaida K, Kobayashi M, Hamada H, Kawamoto M. The severity of sevoflurane-induced malignant hyperthermia. Acta Anaesthesiol Scand. 2012;56:351–6.CrossRefPubMed
7.
Chamley D, Pollock NA, Stowell KM, Brown RL. Malignant hyperthermia in infancy and identification of novel RYR1 mutation. Br J Anaesth. 2000;84:500–4.CrossRefPubMed
8.
9.
Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem. 1988;263:9310–5.PubMed
10.
11.
Fill M, Coronado R, Mickelson JR, Vilven J, Ma JJ, Jacobson BA, et al. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophys J. 1990;57:471–5.CrossRefPubMedPubMedCentral
12.
Rosenberg H, Fletcher J. An update on the malignant hyperthermia syndrome. Ann Acad Med Singap. 1994;23:84–97.PubMed
13.
Jurkat-Rott K, McCarthy T, Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve. 2000;23:4–17.CrossRefPubMed
14.
Krause T, Gerbershagen M, Fiege M, Weisshorn R, Wappler F. Dantrolene–a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59:364–73.CrossRefPubMed
15.
Christiansen LR, Collins KA. Pathologic findings in malignant hyperthermia: a case report and review of literature. Am J Forensic Med Pathol. 2004;25:327–33.CrossRefPubMed
16.
Mezin P, Payen J, Bosson J, Brambilla E, Stieglitz P. Histological support for the difference between malignant hyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br J Anaesth. 1997;79:327–31.CrossRefPubMed
17.
Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg. 2010;110:498–507.CrossRefPubMed
18.
Palmiere C, Mangin P. Hyperthermia and postmortem biochemical investigations. Int J Legal Med. 2013;127:93–102.CrossRefPubMed
19.
20.
21.
Robinson R, Curran J, Hall W, Halsall P, Hopkins P, Markham A, et al. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J Med Genet. 1998;35:196–201.CrossRefPubMedPubMedCentral
22.
Phillips MS, Fujii J, Khanna VK, DeLeon S, Yokobata K, de Jong PJ, et al. The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. Genomics. 1996;34:24–41.CrossRefPubMed
23.
Robinson RL, Brooks C, Brown SL, Ellis FR, Halsall PJ, Quinnell RJ, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat. 2002;20:88–97.CrossRefPubMed
24.
Quane KA, Keating KE, Healy JS, Manning BM, Krivosic-Horber R, Krivosic I, et al. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics. 1994;23:236–9.CrossRefPubMed
25.
Fagerlund T, Ording H, Bendixen D, et al. RYR mutation G1021A (Gly341Arg) is not frequent in Danish and Swedish families with malignant hyperthermia susceptibility. Clin Genet. 1996;49:186.CrossRefPubMed
26.
Litman RS, Rosenberg H. Malignant hyperthermia: update on susceptibility testing. JAMA. 2005;293:2918–24.CrossRefPubMed
27.
Brandom BW. Genetics of malignant hyperthermia. Sci World J. 2006;6:1722–30.CrossRef
28.
Burke W, Pinsky LE, Press NA. Categorizing genetic tests to identify their ethical, legal, and social implications. Am J Med Genet. 2001;106:233–40.CrossRefPubMed
29.
Stowell KM. DNA testing for malignant hyperthermia: the reality and the dream. Anesth Analg. 2014;118:397–406.CrossRefPubMed
30.
31.
Rosenberg H, Rueffert H. Clinical utility gene card for: malignant hyperthermia. Eur J Hum Genet. 2011;19:6.
32.
33.
Musselman ME, Saely S. Diagnosis and treatment of drug-induced hyperthermia. Am J Health Syst Pharm. 2013;70:34–42.CrossRefPubMed
34.
Glahn KPE, Ellis FR, Halsall PJ, Müller CR, Snoeck MMJ, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417–20.CrossRefPubMed
Metadata
Title
Sudden death due to malignant hyperthermia with a mutation of RYR1: autopsy, morphology and genetic analysis
Authors
Wenhe Li
Lin Zhang
Yue Liang
Fang Tong
Yiwu Zhou
Publication date
01-12-2017
Publisher
Springer US
Published in
Forensic Science, Medicine and Pathology / Issue 4/2017
Print ISSN: 1547-769X
Electronic ISSN: 1556-2891
DOI
https://doi.org/10.1007/s12024-017-9925-y

Other articles of this Issue 4/2017

Forensic Science, Medicine and Pathology 4/2017 Go to the issue

Images in Forensics

Biventricular noncompaction cardiomyopathy with malignant arrhythmia as a cause of sudden death

Forensic Forum

Body farms

Images in Forensics

Sudden cardiac death from aortoesophageal fistula: an autopsy case report of a rare complication of thoracic aortic aneurysm

Forensic Forum

Body farms

Images in Forensics

Examples of tramline bruises in clinical forensic medicine

Forensic Forum

Body farms